TABLE 2.

Spearman-rank correlations of preexisting (day –2) anti-gC Ig and IgG4/7 antibodies in nasal secretion and serum with protection from EHV-1 infection outcomes

Parameter	Nasal anti-gC Ig	Nasal anti-gC IgG4/7	Serum anti-gC Ig	Serum anti-gC IgG4/7
Fevera	R = –0.622	R = –0.539	R = –0.747	R = –0.767
	P = 0.0012	P = 0.0065	P < 0.0001	P < 0.0001
Clinical diseaseb	R = –0.443	R = –0.404	R = –0.482	R = –0.465
	P = 0.0304	P = 0.0503	P = 0.0172	P = 0.0222
Virus sheddingc	R = –0.806	R = –0.748	R = –0.816	R = –0.805
	P < 0.0001	P < 0.0001	P < 0.0001	P < 0.0001
Cell-associated viremiad	R = 0.670	R = 0.607	R = 0.759	R = 0.758
	P = 0.0001	P = 0.0017	P < 0.0001	P < 0.0001

^aBody temperature at 60 h p.i. (fever peak).

^bClinical score on day 4 p.i.

^cVirus isolation in nasal secretion (PFU) on day 2 p.i.

^dEHV-1 real-time PCR for the gB gene (cycle threshold [C_T]) in PBMC on day 5 pi.